WGS(GeneDx Holdings Corp.) · 财务报表

WGS(GeneDx Holdings Corp.) 的财务报表:医疗保健,诊断与研究。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$212.19M$234.69M$202.57M$305.45M$427.54M
毛利润−$16.60M−$26.75M$90.01M$194.40M$298.17M
营业利润−$446.15M−$667.65M−$180.60M−$23.21M−$13.08M
净利润−$245.39M−$548.98M−$175.77M−$52.29M−$21.02M
经营现金流−$190.43M−$319.15M−$180.15M−$28.50M$33.28M
自由现金流−$199.83M−$326.31M−$185.40M−$33.99M$14.26M
摊薄每股收益$-74.91$-53.63$-7.23$-1.94$-0.73

GeneDx Holdings Corp. WGS